Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The serotonin-1A (5-HT1A) receptor is among the most abundant and widely distributed 5-HT receptors in the brain, but is also expressed on serotonin neurons as an autoreceptor where it plays a critical role in regulating the activity of the entire serotonin system. Over-expression of the 5-HT1A autoreceptor has been implicated in reducing serotonergic neurotransmission, and is associated with major depression and suicide. Extensive characterization of the transcriptional regulation of the 5-HT1A gene (HTR1A) using cell culture systems has revealed a GC-rich "housekeeping" promoter that non-selectively drives its expression; this is flanked by a series of upstream repressor elements for REST, Freud-1/CC2D1A and Freud-2/CC2D1B factors that not only restrict its expression to neurons, but may also regulate the level of expression of 5-HT1A receptors in various subsets of neurons, including serotonergic neurons. A separate set of allele-specific factors, including Deaf1, Hes1 and Hes5 repress at the HTR1A C(-1019)G (rs6295) polymorphism in serotonergic neurons in culture, as well as in vivo. Pet1, an obligatory enhancer for serotonergic differentiation, has been identified as a potent activator of 5-HT1A autoreceptor expression. Taken together, these results highlight an integrated regulation of 5-HT1A autoreceptors that differs in several aspects from regulation of post-synaptic 5-HT1A receptors, and could be selectively targeted to enhance serotonergic neurotransmission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492 · cited 1×
“[3-7].”
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 14×
“During chronic SSRI treatment, 5- HT1A autoreceptors desensitize [107,115-119], leading to reduced 5-HT1A autoreceptor levels in animal depression models and depressed subjects [110,120-125], and restoration of raphe firing activity and 5-HT release.”
BackgroundInfluentialTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“With current antidepressant treatments, although up to 60% of patients respond, only 30% go on to remission [8-13], and 15% attempt suicide [14,15].”
BackgroundBelmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
The mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059 · cited 1×
“, noradrenaline, dopamine, glutamate, neurotrophins) are indirectly involved in depression [16-21], multiple lines of evidence implicate reduced 5-HT neurotransmission as a primary defect in depression [22-30].”
BackgroundGlobal burden of depressive disorders in the year 2000
Üstün, T. B., Ayuso-Mateos, J. L., Chatterji, S., Mathers, C., & Murray, C. J. L. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.5.386 · Cited by 1,735
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 1×
“For example, acute tryptophan depletion triggers relapse in recovered depressed patients, and elicits a depressed mood in normal subjects, while most antidepressant treatments, including serotonin-selective reuptake inhibitor (SSRIs), increase 5-HT neurotransmission either directly or indirectly [20,31-34].”
BackgroundBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 1×
“With current antidepressant treatments, although up to 60% of patients respond, only 30% go on to remission [8-13], and 15% attempt suicide [14,15].”
BackgroundMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 1×
“With current antidepressant treatments, although up to 60% of patients respond, only 30% go on to remission [8-13], and 15% attempt suicide [14,15].”
Background
Cited by
Impact of early adversity on glucocorticoid regulation and later mental disorders
Strüber, N., Strüber, D., & Roth, G. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.015 · Cited by 173
Nicolas, S., Debayle, D., Béchade, C., Maroteaux, L., Gay, A.-S., Bayer, P., Heurteaux, C., Guyon, A., & Chabry, J. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0210-y · Cited by 73
Albert, P., & Fiori, L. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660740 · Cited by 46
Self-citation
Metadata
- Authors
- Albert, P. R., Le François, B., & Millar, A. M.
- Venue
- Molecular Brain
- Published
- 2011
- Volume
- 4
- Issue
- 1
- Pages
- 21
- ISSN
- 1756-6606 (ISSN-L)
- OpenAlex
- W2146531447
- Cited by
- 150
- References
- 29
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness. https://app.cochat.ai/papers/10.1186/1756-6606-4-21
- The paper
- Albert, P. R., Le François, B., & Millar, A. M. (2011). Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness. Molecular Brain. https://doi.org/10.1186/1756-6606-4-21
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.